Association of Flu specific and SARS-CoV-2 specific CD4 T cell responses in SARS-CoV-2 infected asymptomatic heath care workers.
COVID and T cell immunity
COVID and immune response
COVID19
Flu and COVID
SARS-CoV-2 and Influenza
SARS-CoV-2 antigen specific immunity
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
01 10 2021
01 10 2021
Historique:
received:
05
03
2021
revised:
30
07
2021
accepted:
26
08
2021
pubmed:
18
9
2021
medline:
1
10
2021
entrez:
17
9
2021
Statut:
ppublish
Résumé
Influenza vaccination is widely advocated to avoid infection with influenza virus, a serious respiratory pathogen, and this was greatly emphasized during the raging COVID-19 epidemic. We conducted a study for baseline Flu specific immunity in a group of health care workers with documented past SARs-CoV-2 infection (designated COVID+) with mild or no symptoms and compared them with a control group that had not been infected with SARS CoV-2 (COVID-). Concurrently, we examined flu and SARS-CoV-2 specific T cell responses using the AIM (activation induced molecules) assay by flow cytometry. All COVID+ and 40% COVID- participants exhibited AIM responses to SARS-CoV-2 peptides, but only COVID+ were positive for SARs-CoV-2 antibody. Influenza HIN1 antigen specific CD4 T cells were found in 92% COVID+ and 76% COVID- participants and exhibited a strong direct correlation with SARS-CoV-2 specific CD4 T cells. This observation suggests that influenza specific T cell immunity may impact immune responses to SARS-CoV-2.
Identifiants
pubmed: 34531078
pii: S0264-410X(21)01152-X
doi: 10.1016/j.vaccine.2021.08.092
pmc: PMC8403669
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
6019-6024Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Cell. 2020 May 28;181(5):969-977
pubmed: 32437659
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Am J Med. 2021 Feb;134(2):153-155
pubmed: 33198951
J Infect Dis. 2021 Jul 2;224(1):70-80
pubmed: 33822097
mBio. 2020 Nov 20;11(6):
pubmed: 33219096
J Infect Dis. 2015 Jun 15;211(12):1959-68
pubmed: 25556252
Nat Rev Immunol. 2020 Aug;20(8):457-458
pubmed: 32636479
Int J Environ Res Public Health. 2020 Aug 03;17(15):
pubmed: 32756371
Public Health. 2020 Aug;185:91-92
pubmed: 32590235
Sci Rep. 2020 Jun 22;10(1):10104
pubmed: 32572168
Lancet. 2020 May 16;395(10236):1545-1546
pubmed: 32359402
Cell Host Microbe. 2018 Jan 10;23(1):89-100.e5
pubmed: 29324233
Med (N Y). 2021 Jun 11;2(6):720-735.e4
pubmed: 33821250
Hum Vaccin Immunother. 2020 Sep 1;16(9):2217-2218
pubmed: 32501133
Nat Commun. 2019 Feb 20;10(1):874
pubmed: 30787276
Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17720-17726
pubmed: 32647056
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Nat Rev Immunol. 2020 Jun;20(6):375-388
pubmed: 32132681
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Curr Opin Virol. 2018 Feb;28:43-52
pubmed: 29172107
Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):9065-9
pubmed: 18550812
PLoS Biol. 2019 May 17;17(5):e3000257
pubmed: 31100059
Vaccines (Basel). 2019 Nov 13;7(4):
pubmed: 31766202
Nat Rev Immunol. 2020 Nov;20(11):709-713
pubmed: 33024281
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307